MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions
International Journal of Molecular Sciences · 17.07.2025 · 26 (14) · 6875
DOI: 10.3390/ijms26146875 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.07.2025. Verfasst von Adam Shapira Levy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL 33176, USA. Hauptthemen laut MEDLINE: Glioblastoma, Protein Kinase Inhibitors, Brain Neoplasms, Mitogen-Activated Protein Kinase Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Supported by Intramural Research Program at the National Institute of Neurological Disorders and Stroke at the NIH, Intramural Research Program at the National Institute of Neurological Disorders and Stroke at the NIH.
Abstract (Originalsprache)
The Mitogen-activated protein kinase kinase (MEK) protein family has dual-specificity protein kinases with a myriad of cellular functions that include but are not limited to cell survival, cell division, immunologic response, angiogenesis, and cellular senescence. MEK is crucial in the MAPK signaling pathway, regulating different organ systems, including the CNS. Increased activation and dysregulation of the MEK pathway is reportedly observed in 30% of all malignancies. The diversity of MEK renders it a prime target for inhibition in treating cancer. MEK inhibition has been studied in the context of melanoma, non-small cell lung cancer, breast cancer, and colorectal cancer, among others. The standard treatment for glioblastoma (resection, temozolomide, and radiation) remains relatively futile, which warrants alternative treatment options. Therefore, MEK inhibition has garnered more attention in recent years as investigators have explored its role in treating the most aggressive and most common primary brain tumor, glioblastoma. MEK inhibitors have shown efficacy in pre-clinical investigations as well as some promise in clinical trials which have demonstrated improved overall and progression-free survival. This underscores the potential of MEK inhibition in glioblastoma therapy and represents an area that likely warrants further research. However, there are few comprehensive and unifying reviews discussing the current state of MEK inhibition in glioblastoma therapy. We begin this review by detailing the normal function of MEK as it pertains to the CNS. We then compiled relevant pre-clinical and clinical studies to investigate recent research discussing the role of MEK inhibition in glioblastoma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL 33176, USA.
- Department of Neurosurgery, MedStar Georgetown University Hospital, Washington, DC 20007, USA.
- Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
- Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
ORCID-Profile: Adam Shapira Levy, Shumpei Onishi, Yeshavanth Kumar Banasavadi-Siddegowda
Förderung
- Supported by Intramural Research Program at the National Institute of Neurological Disorders and Stroke at the NIH
- Intramural Research Program at the National Institute of Neurological Disorders and Stroke at the NIH
Zitieren
APA
Levy, A. S., Bryant, J. P., Matichak, D., Onishi, S., & Banasavadi-Siddegowda, Y. K. (2025). MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions. International Journal of Molecular Sciences, 26(14), 6875. https://doi.org/10.3390/ijms26146875
Vancouver
Levy AS, Bryant JP, Matichak D, Onishi S, Banasavadi-Siddegowda YK. MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions. International Journal of Molecular Sciences. 2025;26(14):6875. doi:10.3390/ijms26146875
BibTeX
@article{Levy2025,
author = {Levy, Adam Shapira and Bryant, Jean-Paul and Matichak, David and Onishi, Shumpei and Banasavadi-Siddegowda, Yeshavanth Kumar},
title = {MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {14},
pages = {6875},
doi = {10.3390/ijms26146875}
}
EUVIMED